Evolving Treatment Strategies for EGFR exon 20 Insertion Mutation in NSCLC and Regional Practice Insights from Japan and Taiwan-Evolving Treatment Strategies for EGFR exon 20 Insertion Mutation in NSCLC and Regional Practice Insights from Japan and Taiwan

Video Transcription

Video Summary

Dr. Kuan-Yi Cheng opens a joint educational webinar organized with the Japan Lung Cancer Society, the Taiwan Association for the Study of Lung Cancer, and IASLC, focused on EGFR exon 20 insertion–mutant lung cancer and comparisons of thoracic oncology practice in Japan and Taiwan.<br /><br />Dr. James C-H Yang reviews EGFR exon 20 insertions, which make up ~7% of EGFR mutations and are typically resistant to first-, second-, and third-generation EGFR TKIs due to structural changes near the C-helix that hinder drug binding. He distinguishes proximal vs distal insertion subtypes and notes the complexity of >100 variants. He highlights amivantamab, a bispecific EGFR/MET antibody that promotes receptor internalization and degradation, showing clinically meaningful responses in early studies and improved progression-free survival when combined with chemotherapy in the phase 3 PAPILLON trial, establishing it as a frontline standard. He also discusses emerging bispecific/ADC approaches, toxicity challenges with EGFR-targeting ADCs, and multiple small-molecule inhibitors in development. He presents data for sunvozertinib, including dose considerations (200 mg better tolerated; similar response), FDA accelerated approval, and ongoing confirmatory trials. He concludes that efficacy varies across agents, EGFR wild-type toxicity can limit dosing, and regulatory pathways are crucial.<br /><br />Drs. Shiteito Horinouchi and Bin-Chi Liao compare Japan and Taiwan systems: both have universal insurance, but Taiwan often has reimbursement delays after drug approval, while Japan links approval and reimbursement with copayment caps. Testing strategies differ: Taiwan often uses stepwise PCR first with limited NGS reimbursement; Japan commonly uses upfront multiplex testing, with broader cost protection but restrictions on large panels first-line. They review access to amivantamab regimens, reimbursement rules, and supportive care structures for managing EGFR-related adverse events.<br /><br />Dr. Makoto Nishio closes by emphasizing unmet needs and the value of continued regional collaboration to accelerate evidence generation and implementation.

Asset Subtitle

Video

Keywords

EGFR exon 20 insertion

non-small cell lung cancer

thoracic oncology

amivantamab

PAPILLON trial

bispecific antibody EGFR MET

antibody-drug conjugate EGFR

sunvozertinib

small-molecule EGFR inhibitors

EGFR TKI resistance

NGS multiplex molecular testing

Japan Taiwan reimbursement and access